Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DT433
- Development stage
- Preclinical
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Unknown
01
Overview
DT433 is a DNAzyme therapeutic investigated for its role in targeted gene silencing, specifically focusing on the inhibition of DNMT1 expression and reactivation of tumor suppressor pathways (such as upregulation of p16 mRNA) in cancer cells. DT433 was designed as a catalytic DNA molecule (DNAzyme) to selectively cleave and silence disease-causing RNA. In preclinical studies, DT433 treatment resulted in inhibition of DNMT1, which is linked to epigenetic regulation and tumor progression, and increased p16 mRNA, a key tumor suppressor, suggesting restoration of cell cycle control in cancer models[1]. DNAzymes represent an emerging class of synthetic nucleic acid therapeutics with highly specific RNA targeting capabilities.
- Brand names
- DT433DT-433DT 433
- Other names
- DT433DT-433DT 433
02
Targets
CDKN2A (Cyclin-dependent kinase inhibitor 2A)DNMT1 (DNA (cytosine-5)-methyltransferase 1)
Beyond the preview
Go deeper on DT433.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DT433.